PolarityTE to Report Second Quarter Financial Results on August 12, 2021
PolarityTE, Inc. (Nasdaq: PTE) plans to announce its financial results for the quarter ending June 30, 2021, on August 12, 2021, at approximately 4:00 p.m. Eastern Time. Following the earnings release, a conference call will be held at 4:30 p.m. Eastern Time, accessible via phone and webcast. PolarityTE focuses on developing regenerative tissue products from patients' own tissues, aiming to enhance healing through innovative methods. Their products, including SkinTE, are still in the development phase and are not yet approved for clinical use.
- Scheduled earnings release could reflect positive financial performance.
- Focus on innovative regenerative tissue product development.
- Products are not approved for clinical use, indicating potential market challenges.
- Dependence on future clinical studies and FDA approvals poses risks.
PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the quarter ended June 30, 2021 by press release on Thursday, August 12, 2021 at approximately 4:00 p.m. Eastern Time.
In addition, the Company will host a conference call and webcast with Q&A on August 12, 2021 at 4:30 p.m. Eastern Time. The conference call can be accessed by calling 1-800-581-5838 (U.S. and Canada) or +44 (0)330 336 9104 (International) with confirmation code 210912 and referencing “PolarityTE Second Quarter 2021 Earnings Call.” A webcast of the conference call can be accessed by using the link below.
Earnings Call Webcast – CLICK HERE
A replay of the earnings conference call will be available for 30 days, beginning approximately one hour after the conclusion of the call and can be found by visiting PolarityTE’s website at https://www.polarityte.com/news-media/events, or by clicking on the link above.
About PolarityTE®
PolarityTE is focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures products from the patient's own tissue and uses the patient's own body to support the regenerative process. From a small piece of healthy autologous tissue, the company creates an easily deployable, dynamic, and self-propagating product designed to regenerate the target tissues. PolarityTE's innovative methods are intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing. PolarityTE’s products, including SkinTE, are in the development stage, and are not approved or available for clinical use. Learn more at www.PolarityTE.com – Welcome to the Shift®.
Forward Looking Statements
Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as "believes," "may," "expects," "anticipates," "intend," "plan," "will," "would," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to the impact of the COVID-19 pandemic, future clinical studies, and FDA regulatory matters, which cannot be predicted, and the risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
POLARITYTE, the POLARITYTE logo, SKINTE, WHERE SELF REGENERATES SELF and WELCOME TO THE SHIFT are registered trademarks of PolarityTE, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005143/en/
FAQ
When will PolarityTE report its Q2 2021 earnings?
How can I access the PolarityTE earnings call?
What is the primary focus of PolarityTE's products?
Is SkinTE approved for clinical use?
